Abbott Laboratories
ABT125.460USD
+2.180+1.77%
Fechamento 12/12, 16:00（ET）Cotações atrasadas em 15 min
218.16BValor de mercado
15.62P/L TTM
Mais detalhes de Abbott Laboratories Empresa
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
Informações de Abbott Laboratories
Código da empresaABT
Nome da EmpresaAbbott Laboratories
Data de listagemApr 06, 2073
CEOFord (Robert B)
Número de funcionários114000
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 06
Endereço100 Abbott Park Road
CidadeABBOTT PARK
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal60064-3500
Telefone12246676100
Sitehttps://www.abbott.com
Código da empresaABT
Data de listagemApr 06, 2073
CEOFord (Robert B)
Executivos da empresa Abbott Laboratories
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
50.97K
-0.75%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+4.17%
Ms. Nancy Mckinstry
Ms. Nancy Mckinstry
Lead Independent Director
Lead Independent Director
38.72K
+4.41%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
-2.76%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Outro
4.53B
40.67%
Por RegiãoUSD
Nome
Receita
Proporção
All other Countries
6.87B
61.62%
United States
4.28B
38.38%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Outro
4.53B
40.67%
Distribuição de ações
Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Outro
74.54%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Outro
74.54%
Tipos de investidores
Investidores
Proporção
Investment Advisor
47.15%
Investment Advisor/Hedge Fund
23.09%
Research Firm
3.49%
Pension Fund
2.34%
Bank and Trust
2.20%
Sovereign Wealth Fund
1.37%
Insurance Company
1.02%
Hedge Fund
0.49%
Individual Investor
0.48%
Outro
18.37%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
4606
1.42B
81.82%
+3.92M
2025Q3
4681
1.42B
81.87%
+8.53M
2025Q2
4668
1.41B
81.51%
+6.23M
2025Q1
4636
1.40B
80.10%
+7.18M
2024Q4
4554
1.38B
78.81%
+33.68M
2024Q3
4367
1.35B
78.83%
-5.95M
2024Q2
4376
1.35B
78.36%
+5.03M
2024Q1
4375
1.35B
77.56%
-1.86M
2023Q4
4400
1.34B
77.62%
+7.10M
2023Q3
4258
1.33B
78.26%
-4.16M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
172.03M
9.88%
+2.96M
+1.75%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
88.52M
5.09%
+696.11K
+0.79%
Jun 30, 2025
State Street Investment Management (US)
78.35M
4.5%
+689.52K
+0.89%
Jun 30, 2025
Capital International Investors
60.14M
3.46%
-6.69M
-10.01%
Jun 30, 2025
Capital Research Global Investors
41.77M
2.4%
-8.97M
-17.68%
Jun 30, 2025
Geode Capital Management, L.L.C.
38.29M
2.2%
+1.39M
+3.77%
Jun 30, 2025
Wellington Management Company, LLP
25.05M
1.44%
-4.71M
-15.83%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
22.25M
1.28%
+1.27M
+6.03%
Jun 30, 2025
JP Morgan Asset Management
26.38M
1.52%
-2.42M
-8.39%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 5 de nov
Atualizado em: qua, 5 de nov
Nome
Proporção
iShares U.S. Medical Devices ETF
19.31%
Goldman Sachs Future Health Care Equity ETF
6.26%
SMI 3Fourteen Full-Cycle Trend ETF
5.01%
Invesco Pharmaceuticals ETF
4.99%
Health Care Select Sector SPDR Fund
4.62%
Proshares Ultra Health Care
4.61%
Tema Heart & Health ETF
4.5%
iShares U.S. Healthcare ETF
4.42%
AdvisorShares Focused Equity ETF
4.37%
Polen Capital Global Growth ETF
4.27%
Ver Mais
iShares U.S. Medical Devices ETF
Proporção19.31%
Goldman Sachs Future Health Care Equity ETF
Proporção6.26%
SMI 3Fourteen Full-Cycle Trend ETF
Proporção5.01%
Invesco Pharmaceuticals ETF
Proporção4.99%
Health Care Select Sector SPDR Fund
Proporção4.62%
Proshares Ultra Health Care
Proporção4.61%
Tema Heart & Health ETF
Proporção4.5%
iShares U.S. Healthcare ETF
Proporção4.42%
AdvisorShares Focused Equity ETF
Proporção4.37%
Polen Capital Global Growth ETF
Proporção4.27%
Dividendo
Um total de
16.46B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sep 19, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Nov 17, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 17, 2025
Oct 15, 2025
Jun 13, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 21, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Dec 13, 2024
ABT.NB Final Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 09, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de Abbott Laboratories?
Os cinco principais acionistas de Abbott Laboratories são:
The Vanguard Group, Inc. detém 172.03M Ações, representando 9.88% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 88.52M Ações, representando 5.09% do total de Ações.
State Street Investment Management (US) detém 78.35M Ações, representando 4.50% do total de Ações.
Capital International Investors detém 60.14M Ações, representando 3.46% do total de Ações.
Capital Research Global Investors detém 41.77M Ações, representando 2.40% do total de Ações.
The Vanguard Group, Inc. detém 172.03M Ações, representando 9.88% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 88.52M Ações, representando 5.09% do total de Ações.
State Street Investment Management (US) detém 78.35M Ações, representando 4.50% do total de Ações.
Capital International Investors detém 60.14M Ações, representando 3.46% do total de Ações.
Capital Research Global Investors detém 41.77M Ações, representando 2.40% do total de Ações.
Quais são os três principais tipos de acionistas de Abbott Laboratories?
Os três principais tipos de acionistas da Abbott Laboratories são:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Quantas instituições possuem ações da Abbott Laboratories (ABT)?
Em 2025Q4, 4606 instituições possuíam ações da Abbott Laboratories, com valor de mercado aproximado de 1.42B, representando 81.82% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em -0.05%.
Qual é a maior fonte de receita da Abbott Laboratories?
Em FY2025Q2, o segmento de negócios Diabetes Care gerou a maior receita para Abbott Laboratories, totalizando 1.98B e representando 17.78% da receita total.
